An FDA warning letter lays out failures by a Torrent Pharmaceuticals plant that figures into the global recall of tainted high blood pressure meds.
Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.
Sanofi, which has been testing robots and new production methods, has finally pulled it all together into a near sentient manufacturing operation.
Lupin has named a new global head of quality even as another of its plants gets an FDA Form 483.
Chinese drugmaker BeiGene has opened the first phase of a $320 million facility where it intends to manufacture targeted cancer drugs.
GlaxoSmithKline has decided its time to pull its ranitidine heartburn meds off the shelves in markets where it sells them.
India’s Aurobindo, which has been racking up FDA actions right and left, acknowledged Monday a recent agency inspection resulted in a Form 483.
Johnson & Johnson has expanded its Cork Co., Ireland biologics site with a $350 million facility, adding 200 jobs in the process.
After some recalls of defective creams, India's Glenmark has received a warning letter for the plant where they were manufactured.
French CDMO Delpharm is planning a big expansion with a $274 million deal to pick up five sites from financially struggling Famar.
